'''Dibenzepin''', sold under the brand name '''Noveril''' among others, is a [[tricyclic antidepressant]] (TCA) used widely throughout [[Europe]] for the treatment of [[major depressive disorder|depression]].<ref name="isbn3-88763-075-0">{{cite book | author = Swiss Pharmaceutical Society | title = Index Nominum 2000: International Drug Directory (Book with CD-ROM) | publisher = Medpharm Scientific Publishers | location = Boca Raton | year = 2000 | pages = | isbn = 3-88763-075-0 | oclc = | doi = | url = https://books.google.com/books?id=5GpcTQD_L2oC&lpg=PA323&dq=dibenzepin&as_brr=3&pg=PA323#v=onepage&q=&f=false}}</ref><ref name="isbn0-8155-1144-2">{{cite book | author = Sittig, Marshall | title = Pharmaceutical manufacturing encyclopedia | publisher = Noyes Publications | location = Park Ridge, N.J., U.S.A | year = 1988 | pages = | isbn = 0-8155-1144-2 | oclc = | doi = | url = https://books.google.com/books?id=X2EyLsG4bcUC&lpg=PA470&dq=dibenzepin&as_brr=3&pg=PA470#v=onepage&q=&f=false}}</ref><ref name="pmid1687987">{{cite journal | vauthors = Beresewicz M, Bidzińska E, Koszewska I, Puzyński S | title = [Results of using tricyclic antidepressive drugs in the treatment of endogenous depression (comparative analysis of 7 drugs)] | language = Polish | journal = Psychiatria Polska | volume = 25 | issue = 3-4 | pages = 13–8 | year = 1991 | pmid = 1687987 | doi = | url = }}</ref> It has similar efficacy and effects relative to other TCAs like [[imipramine]] but with fewer [[side effect]]s.<ref name="urlwww.health.gov.il">{{cite web | url = http://www.health.gov.il/units/pharmacy/trufot/alonim/2107.pdf | title = Novartis (dibenzepin) - Prescribing Information}}</ref><ref name="isbn1-4200-4479-6">{{cite book | author = Paloucek, Frank P. | author2 = Leikin, Jerrold B. | title = Poisoning and Toxicology Handbook, Fourth Edition (Poisoning and Toxicology Handbook (Leiken & Paloucek's)) | publisher = Informa Healthcare | location = | year = 2007 | pages = | isbn = 1-4200-4479-6 | oclc = | doi = | url = https://books.google.com/books?id=0Bw2UJTC_uMC&lpg=PA242&dq=dibenzepin&lr=lang_en&as_drrb_is=q&as_minm_is=0&as_miny_is=&as_maxm_is=0&as_maxy_is=&as_brr=3&pg=PA242#v=onepage&q=&f=false}}</ref><ref name="pmid6928">{{cite journal | vauthors = Gowardman M, Brown RA | title = Dibenzepin and amitriptyline in depressive states: comparative double-blind trial | journal = The New Zealand Medical Journal | volume = 83 | issue = 560 | pages = 194–7 |date=March 1976 | pmid = 6928 | doi = | url = }}</ref><ref name="pmid8749">{{cite journal | vauthors = Baron DP, Unger HR, Williams HE, Knight RG | title = A double blind study of the antidepressants dibenzepin (Noveril) and amitriptyline | journal = The New Zealand Medical Journal | volume = 83 | issue = 562 | pages = 273–4 |date=April 1976 | pmid = 8749 | doi = | url = }}</ref>

 
Dibenzepin acts as a [[binding selectivity|selective]] [[norepinephrine reuptake inhibitor]] (NRI), with similar [[potency (pharmacology)|potency]] to that of [[imipramine]].<ref name="pmid1161046">{{cite journal | vauthors = Barth N, Manns M, Muscholl E | title = Arrhythmias and inhibition of noradrenaline uptake caused by tricyclic antidepressants and chlorpromazine on the isolated perfused rabbit heart | journal = Naunyn Schmiedebergs Arch. Pharmacol. | volume = 288 | issue = 2-3 | pages = 215–31 | year = 1975 | pmid = 1161046 | doi = | url = }}</ref> It is also a potent [[antihistamine]].<ref name="pmid6148707" /><ref name="pmid22033803" /> The drug has weak or negligible effects on [[serotonin]] and [[dopamine]] [[reuptake]].<ref name="pmid12111448">{{cite journal | vauthors = Rao ML, Frahnert C, Zagorski O | title = Initial serotonin transport into viable platelets and imipramine binding to platelet membranes | journal = J Neural Transm (Vienna) | volume = 109 | issue = 5-6 | pages = 547–56 | year = 2002 | pmid = 12111448 | doi = 10.1007/s007020200045 | url = }}</ref><ref name="pmid656154" /> Unlike many other TCAs, dibenzepin has no [[antiadrenergic]] ([[alpha-1 adrenergic receptor|α<sub>1</sub>]], [[alpha-2 adrenergic receptor|α<sub>2</sub>]]), [[antiserotonergic]] ([[5-HT1A receptor|5-HT<sub>1A</sub>]], [[5-HT2 receptor|5-HT<sub>2A</sub>]]), or [[antidopaminergic]] effects and has few or no [[anticholinergic]] ({{abbrlink|mACh|muscarinic acetylcholine receptor}}) effects.<ref name="pmid6148707" /><ref name="pmid20647" />
